Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos. Multiple sources of information, they reverse phone lookup provide.
Popular Articles

Oncological Results, Functional Outcomes, Quality-of-Life - Radical Prostatectomy Or External Beam Radiation Therapy For Localized Prostate Cancer
UroToday.com - Most recently, health-related quality-of-life (HRQOL) after definitive local therapy for prostate cancer has been argued in the patient group with an oncological risk category. [1] Prior to such controversy, we thought that posttreatment HRQOL issues or functional outcomes possibly vary among oncological risk categories, and compared both oncological and functional outcomes between patients receiving radical prostatectomy (RP) and those undergoing external beam radiation therapy (EBRT) with risk stratification. [2] Indeed, we found that the low- and intermediate-risk patients in the RP group reported poorer urinary function than those in the EBRT group.
pharmacy online phentermine without prescription
A Single Atom Makes A Big Difference To Purer Water
By substituting a single atom in a molecule widely used to purify water, researchers at Sandia National Laboratories have created a far more effective decontaminant with a shelf life superior to products currently on the market.
News of the day
Vertex Initiates Phase 3 Registration Program For VX-770, An Oral CFTR Potentiator Targeting The Defective Protein Responsible For Cystic Fibrosis
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation of a Phase 3 registration program for VX-770, an investigational Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) potentiator that targets the defective CFTR protein that causes cystic fibrosis (CF). The VX-770 registration program will consist of three clinical trials, including a primary 48-week Phase 3 trial that is currently open to enrollment of patients aged 12 years and older who carry the G551D mutation on at least one allele. Two additional trials will evaluate VX-770 in patients aged 6 to 11 years with the G551D mutation on at least one allele and in patients homozygous for the F508del mutation, respectively.
Cardiovascular

Warning Issued Over Proposed Drug Company Promotion Of Medicines To Public, UK

Drug companies may exploit new rules to promote their products to the public but present it as mere provision of information, according to an editorial published this week in the Drug and Therapeutics Bulletin (DTB). Direct advertising of prescription-only medicines to the public is currently not allowed in the European Union (EU), but this position may be undermined by proposals from the European Commission (EC). The proposals, if agreed, would allow drug companies new opportunities to present the public with information about prescription-only medicine through the internet or yet-to-be-defined "health-related publications." The DTB editorial is concerned about the proposals, which it suggests would permit direct advertising to the public in spite of the EU-wide ban. It is proposed that each EU member state would ensure the companies providing the information were monitored and this could involve self-regulation by the companies. "A key concern about these ideas is the intrinsic difficulty in distinguishing between advertising of prescription-only medicines to the public (which would still be banned) and proactive provision of non-promotional information about such products," says the editorial. The UK medicines regulator, the Medicines and Healthcare products Regulatory Agency, is currently carrying out a public consultation on this issue - due to finish on August 14 - but supports the principle of allowing the pharmaceutical industry to give patients more information about medicines. DTB, however, cites the negative experience in the US with direct to consumer advertising, where "infringements of rules on information provision have tended to be detected far too late and where there have been difficulties in imposing effective penalties." The editorial concludes: "We believe that acceptance of the EC"s proposals would permit public dissemination of promotional information about prescription-only medicines, masquerading as "information provision"." Given the obvious conflict of interests, DTB concludes, it would be naç¯ve to think that the pharmaceutical industry would provide independent and reliable information to allow people to make informed choices about treatment. "How to misinform patients." DTB 2009; doi 10.1136/dtb.2009.07.0027 Drug And Therapeutics Bulletin


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009